ERBB2 and gastric cancer: A number of randomized phase III trials testing target therapies in the treatment of advanced GC patients have been performed in clinics, including anti-HER2 targeted agents, angiogenesis inhibitors, EGFR inhibitors, and mTOR inhibitors [5–7, 9].